Elamipretide vs L-692,429
Head-to-head comparison of Elamipretide (Elamipretide (MTP-131, SS-31)) and L-692,429 (L-692,429) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Elamipretide | L-692,429 |
|---|---|---|
| Category | Muscle & Performance | Growth Hormone |
| Full Name | Elamipretide (MTP-131, SS-31) | L-692,429 |
| Molecular Weight | 639.8 Da | N/A |
| Half-Life | 1-4 hours | unknown / study-dependent |
| Amino Acids | 4 | N/A |
| Typical Dose | 0.01-0.25 mg/kg/day | 0.03-0.1 mg/kg |
| Route | Subcutaneous/Intravenous | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 120 | 30 |
| Research Status | Clinical | Pre-clinical |
Elamipretide Benefits
- ✓mitochondrial protection
- ✓reduced oxidative stress
- ✓improved fatigue resistance
- ✓may support exercise tolerance
L-692,429 Benefits
- ✓potent GHSR agonism
- ✓oral bioactivity in models
- ✓validates ghrelin pathway
- ✓useful research probe
Elamipretide Dosing
0.01-0.25 mg/kg/day SC (clinical research)|daily dosing in trials|alternative IV protocols in some studies
L-692,429 Dosing
0.03-0.1 mg/kg in early studies|single oral or short-course research dosing|serial GH sampling recommended
Elamipretide Side Effects
- ⚠nausea
- ⚠injection-site reactions
- ⚠diarrhea
- ⚠headache
L-692,429 Side Effects
- ⚠increased appetite
- ⚠glucose intolerance
- ⚠transient prolactin changes
Research Overview
Elamipretide
Clinical and translational studies show elamipretide can improve mitochondrial function and some functional endpoints in mitochondrial disorders. Skeletal muscle research suggests benefits are driven by energy metabolism rather than direct muscle-building effects.
L-692,429
L-692,429 was important in early GH secretagogue research because it showed that nonpeptide molecules could trigger robust GH release. It remains a classic tool compound for studying receptor-mediated GH pulsatility and appetite signaling.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.